Rasmus Holm-Jorgensen
Direttore Finanziario/CFO presso ACRIVON THERAPEUTICS, INC.
Patrimonio netto: 230 875 $ in data 30/04/2024
Posizioni attive di Rasmus Holm-Jorgensen
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Direttore Finanziario/CFO | 01/04/2022 | - |
Storia della carriera di Rasmus Holm-Jorgensen
Precedenti posizioni note di Rasmus Holm-Jorgensen
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Fondatore | 01/07/2015 | 01/04/2022 |
| Corporate Officer/Principal | 01/07/2015 | 01/04/2022 | |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01/01/2011 | 01/01/2015 |
Formazione di Rasmus Holm-Jorgensen
| University of Copenhagen | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
| Danimarca | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
| Founder | 1 |
| Graduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
